Search research articles
Contact Us
Filters
Showing results (61-70 of 242) with videos related to
Page
of 25
Sort By:
Blood Cancer Journal
|
April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
Surbhi Sidana, Paolo Milani, Moritz Binder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2005
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis
Luis F Porrata, Morie A Gertz, Mark R Litzow, et al.
Blood
|
September 30, 2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri, Martha Q Lacy, Steven R Zeldenrust, et al.
American Journal of Hematology
|
June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood
|
December 24, 2005
Clinical implication of centrosome amplification in plasma cell neoplasm
Wee J Chng, Greg J Ahmann, Kim Henderson, et al.
Blood Cancer Journal
|
November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2020
Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
Abdullah S Al Saleh, M Hasib Sidiqi, Eli Muchtar, et al.
Blood
|
August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
S Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
American Journal of Hematology
|
July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapies
Neil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal
|
January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patients
Nadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.
Page
of 25
Search research articles
Search
Showing results (61-70 of 242) with videos related to
Sort By:
Page
of 25
Blood Cancer Journal
|
April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
Surbhi Sidana, Paolo Milani, Moritz Binder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2005
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis
Luis F Porrata, Morie A Gertz, Mark R Litzow, et al.
Blood
|
September 30, 2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri, Martha Q Lacy, Steven R Zeldenrust, et al.
American Journal of Hematology
|
June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood
|
December 24, 2005
Clinical implication of centrosome amplification in plasma cell neoplasm
Wee J Chng, Greg J Ahmann, Kim Henderson, et al.
Blood Cancer Journal
|
November 27, 2021
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2020
Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
Abdullah S Al Saleh, M Hasib Sidiqi, Eli Muchtar, et al.
Blood
|
August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
S Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
American Journal of Hematology
|
July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapies
Neil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal
|
January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patients
Nadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.
Page
of 25